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tolic function were recorded.All had confirmed normal short axis systolic contractility.
Diastolic function was studied by means of tissue doppler.
Results: Echocardiographic indices were predictably abnormal, and plasma MMP-9 &
TIMP-1 were elevated in HT. Within the hypertensive cohort, LV mass and septal thick-
ness correlated positively with TIMP-1 (Ranked Pearson’s correlation r=0.312,p=0.035;
r=0.359,p=0.013 respectively). There was a negative correlation between e’ and TIMP-1
(r= -0.296,p=0.037).
Conclusion: We have defined a novel relationship between elevated TIMP-1, increased
LV mass and impaired diastolic relaxation. This suggests a role for this metalloproteinase
inhibitor in the patho-physiology of hypertensive heart disease potentially related to dias-
tolic heart failure in HT.
1142-187 Three-Dimensional Echocardiographic and Magnetic 
Resonance Assessment of the Effect of Telmisartan 
Compared With Carvedilol on Left Ventricular Mass: A 
Multicenter, Randomized, Controlled Study
Domenico Galzerano, Luca Del Viscovo, Paolo Tammaro, Carlo Tedeschi, Roberto 
Breglio, Diana Lama, Antonio Cerciello, Bernardino Tuccillo, Paolo Capogrosso, San 
Gennaro Hospital, Naples, Italy
Background: Meta-analyses examining hypertensive left ventricular hypertrophy (LVH)
suggest that the observed regression of LVH is related not only to blood pressure control,
but also to drug-related effects.
Objective: To elucidate the efficacy and the effects on left ventricular mass of different
classes of drugs, on the hypothesis that blockade of angiotensin II type 1 (AT1) receptors
by the AT1 receptor antagonist telmisartan (TEL) would reduce left ventricular mass
assessed by three-dimensional echocardiography (3DE) and magnetic resonance imag-
ing (MRI) more than conventional treatment with the beta-blocker carvedilol (CARV).
Design and Methods: This study randomized 80 patients with mild-to-moderate hyperten-
sion plus LVH and optimal acoustic window to receive either TEL 80 mg od or CARV 25
mg od for 40 weeks. Ten patients withdrew from the study because diastolic blood pres-
sure remained above 90 mmHg. At baseline and after the 40-week treatment, blood
tests, 3DE and 24-h ABPM were performed. 28 patients underwent MRI.
RESULTS: Systolic and diastolic blood pressure reductions were similar in both treat-
ment groups(before and after TEL: 160±9.5and 97.8±5.8 vs 128±6.5/77.3±5.4 mmHg;
CARV: 160±10.7 and 95.4±4.9 vs 128.4±4.9 and 78.3±4.8 mmHg). Both TEL (P<0.001)
and CARV (P<0.01) progressively reduced left ventricular mass index by 22 and 12 g/m2
(15% and 9%), respectively, at week 40 (P=0.02). A higher percentage of normalized left
ventricular mass was achieved in the TEL group (44% vs 30%).
CONCLUSIONS: TEL produced a greater reduction of left ventricular mass than CARV,
suggesting that AT1 receptor blockade provides an important mechanism, beyond that of
lowering blood pressure, in the regression of left ventricular mass in hypertensive
patients.
1142-188 Pulse Wave Velocity Measured by Complior Method in a 
Brazilian Young Population Followed-Up for a 13 Year-
Period: The Rio de Janeiro Study
Oswaldo Pizzi, Roberto Pozzan, Andréa Brandão, Maria Eliane Magalhães, Elizabete 
Freitas, Ayrton Brandão, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 
Medical School of Petrópolis, Petrópolis, Brazil
Background: Vascular injury in youth associated to early blood pressure (BP) alterations
and other risk factors is not well known. To establish their possible association, pulse
wave velocity (PWV), clinical, metabolic and haemodynamic variables were measured in
young adults stratified by their blood pressure percentile obtained 13 years earlier.
Methods: 385 young subjects (201M) were evaluated at their schools in 1987-88
(12.74±1.65 y). BP was measured 3 times, and the third measure was used for analysis.
Body mass index (BMI) was obtained. In 1997-2000 (21,91±2,12 y), they were examined
at the hospital. BP, BMI, waist and hip were obtained and cholesterol (C), tryglicerides,
LDL-C, HDL-C, creatinine, plasma glucose and insulin were measured after a 12h fast-
ing. A sample of 60 young adults underwent PWV measurement by Complior method
and was stratified according to their former (at school) BP percentile: Group 1 < 50th per-
centile (n=25, 11 M) and Group 2 > 95th percentile (n=35, 19 M).
Results: 1) Group 1 had higher age (p<.05) and all comparisons were adjusted for age.
2) Group 2 had higher weight (p<.05), systolic BP (SBP) (p<.03), diastolic BP (DBP)
(p<.02), mean BP (MBP) (p<.02), PWV (p<.03), fasting glucose (p<.03) and lower HDL-C
(p<.03). 3) PWV correlated positively and significantly with SBP (r=0.333, p<.02), MBP
(r=0.303, p<.02) and heart rate (HR) (r=0.284, p<.03) obtained 13 years earlier. 4) PWV
showed significant correlations with the following current variables: weight (r=0.403,
p<.01), height (r=0.301, p<.02), waist circumference (r=0.347, p<0.01), waist/hip ratio
(r=0.328, p=0.01), SBP (r=0.444, p<.01), DBP (r=0.318, p<.02), pulse pressure (PP)
(r=0.274, p<.04), MBP (r=0.424, p<.01) and serum creatinin (r=0.400, p<.01). 5) In co-
variance analysis, when PWV was adjusted for current SBP, DBP, MBP and PP, no signif-
icant differences were observed between the groups, although group 2 showed higher
means in all comparisons.
Conclusion: High BP percentile obtained in adolescence was associated with higher BP
and PWV 13 years later. These results suggest that early vascular changes could be
identified in young and emphasize that primary prevention must begin early in life.
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847-1 Constellation of Risk Variables of Metabolic Syndrome 
at Low Levels in Childhood Is Beneficially Associated 
With Adulthood Cardiovascular Risk: The Bogalusa 
Heart Study
Wei Chen, Sathanur R. Srinivasan, Shengxu Li, Jihua Xu, Gerald S. Berenson, Tulane 
University Health Sciences Center, New Orleans, LA
Background: Most epidemiologic studies have focused on the association between the
adverse levels of risk variables of metabolic syndrome and the risk of cardiovascular (CV)
disease. However, information is lacking on the relation of metabolic syndrome risk vari-
ables clustering at favorable levels in childhood and CV disease risk in adulthood.
Methods: The study cohort (n=1,474) was examined in childhood (4-17 years) and again
in adulthood (18-41 years), with an average follow-up period of 15.8 years in a black-
white community. The childhood criterion metabolic syndrome variables included the low-
est quartiles (specific for age, race, sex and study year) of body mass index, homeostasis
model assessment of insulin resistance, systolic blood pressure and total cholesterol/
high-density lipoprotein cholesterol ratio. The measures of CV risk in adulthood included
prevalence of metabolic syndrome, parental histories of CV disease, and carotid artery
intima-media thickness (IMT) measured in a subsample (n=138).
Results: In childhood, 9% of the cohort displayed clustering of 3 or 4 criterion risk vari-
ables at the bottom quartiles, which was significantly higher than expected by chance
alone (P<0.01). These children, compared with those without any risk variables at the
bottom quartiles, had a lower prevalence of metabolic syndrome in adulthood (2.3% vs
20.0%, P<0.001). In addition to lower odds for having metabolic syndrome in adulthood
(11-fold, P<0.001), they also displayed lower odds for having parental histories of CHD
(1.9-fold, P=0.039), hypertension (1.5-fold, P=0.045 ) and type 2 diabetes (1.6-fold,
P=0.079). Mean values of carotid IMT in adulthood decreased with an increasing number
of risk variables clustering at the bottom quartiles in childhood (P for trend=0.013).
Conclusion: The constellation of metabolic syndrome variables at low levels in child-
hood is associated with lower measures of CV risk in adulthood. The beneficial conse-
quence of such a lifetime low-risk profile in youth reinforces the importance of CV
disease health promotion and life style modification in early life.
2:15 p.m.
847-2 Combination Aspirin and Statin Therapy Markedly 
Reduces C-Reactive Protein Levels in a High-Risk 
Population Without Coronary Disease
Marlene S. Williams, Lewis C. Becker, Taryn F. Moy, Lisa R. Yanek, Nauder Faraday, 
Diane M. Becker, Johns Hopkins Medical Institution, Baltimore, MD
Background: There remains controversy about the anti-inflammatory effects of both low
dose aspirin (ASA) (81mg) therapy and statins and little is known of their combined
effect. This study was designed to determine the extent to which chronic low dose ASA
therapy, statin therapy, and combined statin and ASA therapy have an anti-inflammatory
effect as determined by plasma levels of high sensitivity C-reactive protein (hs-CRP) in a
high-risk population without coronary artery disease (CAD). Methods: We examined 699
asymptomatic siblings (SIBS) of probands with documented CAD < 60 years of age.
SIBS were 49.0 ± 8 years of age, 59% African American, and 41% male and were not
using regular nonsteroidal or other anti-inflammatory agents. Plasma levels of hs-CRP
were measured by ELISA. Three separate multivariate regression models were used,
one each for the use of ASA alone, statins alone, and combination therapy, each control-
ling for age, sex, race, systolic blood pressure, LDL-cholesterol, smoking, diabetes, and
body mass index. Each model contained only people using the specific therapy of inter-
est, plus nonusers. Results: Lower levels of hs-CRP were observed in individuals using
ASA alone (N=23) hs-CRP= 2.1± 1.8 µg/ml, statins alone(N=56) hs-CRP=2.8± 2.6 µg/ml,
and the combination of both statins and ASA(N=13) hs-CRP=1.4± 1.4 µg/ml, in compari-
son with nonusers (N=607) hs-CRP=3.1± 3.0 µg/ml. Combined therapy was the stron-
gest independent predictor of lower hs-CRP levels (p=0.0008). For people using statins
alone, the multivariate adjusted significance was lower, (p=0.007), and for people using
Differences between controls and hypertensives
Controls (n=24) Hypertensives (n=52) p-value
SBP 127(16) 154(22) <0.0001
DBP 79(10) 90(13) <0.001
Cholesterol (mmol/l) 5.7 (5.1-6.1) 5.2 (4.8-6.1) 0.33
LV mass (gm) 182 (68) 231 (85) 0.009
IVRT (msec) 110(99-130) 122(106-143 0.39
E-wave(cm/sec) 0.73(0.15) 0.81(0.02) 0.03
A-wave (cm/sec) 0.67(0.03) 0.83(0.02) <0.001
e' wave(cm/sec) 0.1(0.078-0.12) 0.08(0.07-0.1) 0.009
e'/a' 7.4(2.2) 9.2(2.5) 0.002
MMP-9 42(35-103) 70(45-135) 0.029
TIMP-1 290(230-350) 380(273-580) 0.005
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low dose ASA alone, the multivariate adjusted significance was 0.01. Conclusion: In a
healthy population without known coronary disease, after controlling for major risk fac-
tors, the use of ASA and a statin alone remains significantly associated with lower levels
of inflammation, and importantly the combination of both a statin and aspirin is a particu-
larly strong independent predictor of lower levels of hs-CRP. These findings suggest that
daily statin and aspirin therapy combined may be particularly potent in reducing inflam-
mation in high risk individuals who have not yet had a clinical coronary event.
2:30 p.m.
847-3 Aspirin Resistance Is Associated With a Single 
Nucleotide Polymorphism in the P2Y1 ADP Receptor 
Gene
Brian K. Jefferson, Jennifer H. Foster, Jeanette J. McCarthy, Kandice Kottke-Marchant, 
Eric J. Topol, The Cleveland Clinic Foundation, Cleveland, OH, San Diego State 
University, San Diego, CA
Background: Lack of platelet aggregation response to aspirin resistance (AR) has been
reported in 5-30% of patients. Using strict criteria for AR, we have shown a three fold
increased risk of death, MI and CVA. The underlying mechanisms for the variable effect
of aspirin remain unclear and are likely multi-factorial. Polymorphisms in platelet surface
receptors may alter the response of platelets to pharmacologic agents and play a role in
aspirin sensitivity.
Methods: We examined 7 candidate single nucleotide polymorphisms in the COX-1,
COX-2, GPIIIa, and P2Y1(P2RY1) genes in 332 patients on aspirin with a history of MI
from the Gene Quest 2 database. Aspirin resistance was assessed using optical aggre-
gation in response to arachidonic acid and ADP. Aspirin sensitive (aggregation <20%)
and resistant (>20%) subjects were compared using multiple logistic regression. DNA
was genotyped using standard PCR techniques.
Results: In the study population, 235(71%) were classified as aspirin sensitive and
95(29%) were classified as aspirin resistant. Clinical comparisons between aspirin sensi-
tive and aspirin resistant patients revealed a significant difference between the groups in
age (63.3 y/68.4 y), HDL cholesterol (39 mg/dl/35.6 mg/dl), and incidence of diabetes
(22%/37%). Using logistic regression analysis, patients with the P2RY1 C/T893 genotype
displayed a statistically significant 3-fold higher risk of aspirin resistance over those with
the P2RY1 C/C893 genotype. The risk of aspirin resistance remained even after adjust-
ing for the above confounding variables: Adjusted OR 2.72 (95% C.I. 1.12, 6.57). Single
nucleotide polymorphisms in other candidate genes were not associated with aspirin
resistance.
Conclusions: There are demographic differences between aspirin sensitive and aspirin
resistant patients which are in agreement with previous reports. After controlling for these
variables, the P2RY1 C/T893 polymorphism is associated with decreased platelet
responsiveness to aspirin. Polymorphisms in the P2Y1 receptor gene may provide a
genetic link in the variable clinical responsiveness of patients to aspirin and requires con-
firmation and elucidation of the mechanism.
2:45 p.m.
847-4 Asymmetric Dimethylarginine and the Risk of Coronary 
Heart Disease: Relationship With Traditional Risk 
Factors as Assessed in the Multicenter CARDIAC Study
Rainer H. Boger, Henrike Lenzen, Christoph Hanefeld, Asja Bartling, Karl J. Osterziel, 
Magda Kusus, Caroline Schmidt-Lucke, Dietrich Strodter, Jurgen Berger, Lilia Goudeva, 
Andreas Mugge, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO
synthase. In human subjects, its levels are related to endothelial dysfunction and the pro-
gression of carotid atherosclerosis. In patients with end-stage renal disease, ADMA is
prospectively associated with the risk of major cardiovascular events and death.
It was the aim of the CARDIAC study (Coronary Artery Risk Determination investigating
the Influence of ADMA Concentration) to assess the relationship between ADMA con-
centration and the risk for coronary heart disease (CHD) in a large population including
subjects with a broad range of established coronary risk factors of both sexes and with
normal renal function. We also studied the relationship between ADMA and traditional
risk factors in risk determination.
Methods. 408 patients with established CHD and 408 controls matched for age and sex
were enrolled. Besides traditional risk factors, plasma levels of ADMA and its biologically
inactive regioisomer, symmetric dimethylarginine (SDMA), and L-arginine were deter-
mined.
Results. CHD patients had significantly higher ADMA plasma concentration than controls
(median, 0.91 vs. 0.70 µmol/L; p<0.0001). ADMA was an independent predictive factor
for the risk of CHD, whereas SDMA was not associated with CHD. ADMA levels signifi-
cantly increased with increasing number of established cardiovascular risk factors
present (p<0.01). The presence of hypertension was associated with significantly higher
ADMA levels (median, 0.95 vs. 0.87 µmol/l; p<0.05), whereas hypercholesterolemia was
associated with lower ADMA (0.85 vs. 1.03 µmol/l; p<0.05; probably due to the high rate
of treated hypercholesterolemia), and diabetes mellitus had no significant effect on
ADMA. Former smokers had higher ADMA than current smokers or non-smokers (1.16
vs. 0.70 and 0.88 µmol/l, respectively; p<0.01).
Conclusions. The present data show for a large group of subjects of both sexes and with
a broad range of established coronary risk factors that ADMA is an independent marker
of CHD. Thus, determination of ADMA may help to identify patients at risk for coronary
events beyond currently established risk factors.
3:00 p.m.
847-5 Systolic Blood Pressure Measured Serially From 
Childhood to Adulthood Predicts Arterial Stiffness in 
Young Adults: The Bogalusa Heart Study
Shengxu Li, Wei Chen, Sathanur R. Srinivasan, Gerald S. Berenson, Tulane University, 
New Orleans, LA
Backgroud: Arterial stiffness is associated with cardiovascular risk factors and is an
independent predictor of cardiovascular disease and events even after adjusting for other
traditional risk factors. However, no data are available regarding the relationship of arte-
rial stiffness in young adults to different risk factors measured in childhood, adulthood, or
as a cumulative burden from childhood to adulthood.
Methods: The study sample included 839 young adults (72% whites, 44% males) aged
24 to 44 years who had at least four measurements of traditional risk factors including
body mass index (BMI), systolic blood pressure, low- and high-density lipoprotein (LDL
and HDL) cholesterols, and triglycerides since childhood. The average follow-up period
was 26.5 years. Brachial to ankle pulse wave velocity (baPWV) by oscillometric method
was used as a measure of arterial stiffness. Cumulative burden of risk factors since child-
hood was measured as area under the curve divided by follow-up years.
Results: Males vs females and black vs whites had higher levels of baPWV (P<0.001).
Systolic blood pressure, BMI, and HDL cholesterol measured in childhood, all the risk
factors measured in adulthood, and cumulative burdens of systolic blood pressure, trig-
lycerides, BMI, and HDL cholesterol were significant risk factors for baPWV in young
adults in univariate analyses. In multiple regression analyses, childhood systolic blood
pressure, adulthood systolic blood pressure and triglycerides, and cumulative burdens of
systolic blood pressure and triglycerides since childhood were significant and indepen-
dent risk factors for baPWV in young adults.
Conclusion: These results indicate that among the traditional cardiovascular risk factors,
systolic blood pressure measured either in childhood, adulthood, or as a cumulative bur-
den since childhood is a consistent predictor of arterial stiffness in young adults, and
underscores its importance in the process of arterial stiffening.
3:15 p.m.
847-6 Serum Inflammatory Markers Correlate With 
Hemoglobin Levels in Women Undergoing Evaluation 
for Suspected Ischemia: Results From the National 
Heart, Lung, and Blood Institute WISE Study
Christopher B. Arant, Timothy R. Wessel, Marian B. Olson, Steven E. Reis, Oscar 
Marroquin, C. Noel Bairey Merz, George Sopko, William J. Rogers, Barry L. Sharaf, 
Karen M. Smith, Sunil Mankad, B. Delia Johnson, Eileen Handberg, Carl J. Pepine, The 
WISE Investigators, University of Florida College of Medicine, Gainesville, FL, University 
of Pittsburgh Medical Center, Pittsburgh, PA
Background: Serum inflammatory markers such as C-reactive protein have been shown
to predict cardiovascular morbidity and mortality. Anemia is emerging as a risk factor for
morbidity and mortality in patients presenting with acute myocardial infarction or heart
failure, and other WISE data indicates that lower hemoglobin levels are significantly
associated with worse cardiovascular outcomes. However, the relationship between
serum inflammatory markers and hemoglobin levels in women presenting with chest pain
is not known.
Methods: As part of the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation
(WISE), we collected data including baseline hemoglobin level, high sensitivity C-reactive
protein (CRP), IL-6, and TNF-alpha levels in 602 women referred for coronary angiogra-
phy to evaluate suspected ischemia. We then compared the hemoglobin levels with
serum inflammatory marker levels.
Results: Of the women enrolled, the mean age was 58.0 + 11.7 yrs, and 35% had angio-
graphic CAD stenoses of >50%, 26% had diabetes, 58% had hypertension, 54% had
dyslipidemia, and 20% were current smokers. As hemoglobin levels increased, serum
inflammatory marker levels including CRP (p=0.05), IL-6 (p=0.005), and TNF-alpha
(p=0.009) decreased. A hemoglobin <12 g/dL was also associated with significantly
higher levels of CRP (p=0.02), IL-6 (p<0.001), and TNF-alpha (p=0.006). After adjusting
for waist/hip ratio, lipid levels, statin use, ACE-inhibitor use, aspirin or other antiplatelet
medication use, and angiographic CAD, hemoglobin <12g/dL was associated with
increased CRP (p=0.07), IL-6 (p< 0.01), TNF-alpha (p<0.01).
Conclusions: Serum inflammatory markers are inversely related to hemoglobin levels in
this population of women evaluated for suspected ischemia. Underlying inflammation
may contribute to both decreased hemoglobin levels and increased cardiovascular mor-
bidity and mortality found in this population of women.
